Chronic total occlusion angioplasty: no more excuses

Chronic total occlusion percutaneous intervention (CTO-PCI) technique has evolved coincident with improvements in success rate and safety of the procedure. Despite this, many patients are not offered this treatment even after medical therapy fails to alleviate their symptoms. The frequently stated reasons for this include the absence of randomized trial data, excessive costs and the time burden of the procedures. In this article our aim is to dispel the myths surrounding the benefits, costs and time burden of CTO-PCI and suggest that these excuses for not attempting CTO-PCI should be avoided so that patients receive the treatment they need, not simply the treatment their provider or institution prefers.

‘Why didn’t my doctor recommend this 3 years ago?’ asked Mr J the day after successful chronic total occlusion (CTO) angioplasty. Mr J had suffered with angina after failure of his saphenous vein graft to the right coronary artery (RCA) left him with a ‘well collateralized’ CTO 3 years earlier. His local cardiologist placed him on three anti-anginal drugs and told him ‘nothing more can be done’. After two visits to the emergency department, two stress tests confirming RCA ischemia, a repeat cardiac catheterization reconfirming the only culprit to be the CTO of the RCA, even a stent placement to the grafted left anterior descending artery (LAD) providing him with no benefit, Mr J’s family convinced him to seek a second opinion. Questions similar to this are frequently posed by grateful patients after successful CTO-PCI. The answer is complicated: evidence suggests that patients with CTOs are being treated or not treated based on physician preference and institutional biases, not their needs; many excuses are given for not treating appropriate patients with PCI; the real problem is that physicians have not been taught how to treat them with PCI and achieve high success rates and low complication rates when PCI is deemed appropriate. The problem is worthy of consideration since CTOs are discovered in 18% of patients referred for coronary angiography but account for less than 5% of all angioplasties performed in real world PCI registries.

Physician preference & institutional bias influences CTO-PCI decision-making

There is evidence that the presence of a CTO drives the decision-making over how to treat a patient with coronary artery disease. In the Bypass Angioplasty Revascularization Investigation (BARI) registry, when non-CTO disease was discovered PCI was performed approximately 35% of the time, while when a CTO was discovered, 10% of patients were treated with PCI and a larger proportion were treated with medical therapy.

Using the National Cardiovascular Disease Registry’s CathPCI Registry we found that operator PCI volume was independently associated with CTO-PCI attempt rate such that low volume operators (<50 PCIs/year) were half as likely as intermediate (50–200 PCIs/year) or high volume (>200 PCIs/year) operators to attempt a CTO once discovered. In a Canadian registry, one center performed PCI for 1% of patients with a CTO, and another center performed PCI in...
16% of patients with a CTO. While treatment variability may represent under or overutilization, it is reasonable to suggest that the hospital treating only 1% of cases with PCI may be underutilizing PCI given the multitude of barriers to CTO-PCI performance, including operator preference. Operator- and institutional-based variability is not justifiable since there is no difference between the symptom-relieving benefits of PCI when a vessel is 100% compared with those that are sub-totally occluded [5].

Taken together, these observations support our contention that many patients with CTOs such as Mr J, are treated according to operator- and institutional treatment biases, not their clinical needs. The real concern in his case was that he was not referred by his cardiologist to a center with CTO-PCI capabilities; he was simply told that ‘nothing more can be done’.

Excuses for not offering CTO-PCI
There are two commonly used reasons for not offering appropriately selected patients CTO-PCI or referring them to a CTO center. Operators cite insufficient evidence of benefits and express concerns related to economic barriers of CTO-PCI.

CTO-PCI evidence of benefit
It is true that there is a paucity of evidence from randomized trials proving the benefits of CTO-PCI as compared with medical therapy. The OAT trial, which indicated that PCI of an occluded culprit artery 3–28 days after myocardial infarction did not reduce the occurrence of death, reinfarction or heart failure during 4 years of follow-up [6], is often misapplied. OAT did not study CTOs, rather recent occlusions and OAT-excluded patients with evidence of large ischemic territories or symptoms suggestive of ischemia and/or viability, the primary therapeutic targets for CTO-PCI.

Because of this lack of randomized trial data some cardiologists still choose to ignore the evidence that does exist. There has been an emphasis on whether successful CTO-PCI improves mortality. The studies describing an association between successful CTO-PCI and survival compared with unsuccessful CTO-PCI are summarized in Table 1. They all suffer from the same limitations. The failure groups may represent a different cohort, with higher lesion complexity and disease burden resulting in poorer outcomes, among other confounders. The controversy is furthered by disparate findings between studies. Fefer et al. suggest that the presence of a CTO is not independently associated with an adverse long-term outcome, and failure to revascularize a non-LAD CTO is not associated with a higher mortality [7].

Differences in patient or angiographic characteristics in the non-revascularized group may account for overall increased mortality. While Godino et al. found that non-revascularized patients (those without an attempt and failed procedures) experienced a higher rate of cardiac mortality and sudden cardiac death compared with those with successful revascularization. Within the non-revascularized cohort, the presence of low-left ventricular ejection fraction (LVEF), chronic renal failure, or diabetes were associated with a fourfold increased risk of cardiac death as compared with those without the same risk factors [8]. Recently a meta-analysis of all of these studies suggests that CTO-PCI success as compared with failure is associated with mortality (Table 1; Khan et al. [55]). Thus each asymptomatic patient should be considered individually based on their risk profile. The indications, risks and limitations of the available evidence supporting CTO-PCI for survival advantage should be discussed in a balanced way. Simply saying ‘there is no data’ is just as disingenuous as saying there is proof of a survival advantage of CTO-PCI. Patients deserve the full story and the opportunity to engage in fully informed shared decision-making.

The studies confirming the symptom relieving potential of CTO-PCI are compelling and summarized in Table 1 as well. Again there is a paucity of randomized controlled trial data but the recent finding by Safley et al. [9] that CTO patients derive similar self reported quality of life improvements as compared with non-CTO patients after PCI leads one to wonder why there should be a double standard between CTO and non-CTO disease revascularization rates. We often challenge operators to ask themselves, ‘if it were 90% would you stent it?’ This decision should be based entirely on the patient’s symptoms, risk, and response to medical therapy, not the angiographic severity of the stenosis in the culprit artery.

Other reported advantages of CTO-PCI include improved left ventricular function (Table 2), and avoidance of other procedures such as coronary artery bypass grafting (CABG), automatic implantable cardioverter defibrillators (AICDs) and cardiac transplant [9,10]. These studies are also summarized in Table 1. These multiple registries and studies have been considered by the American College of Cardiology (ACC), American Heart Association (AHA), and The Society for Cardiology Angiography and Interventions (SCAI) in their indications and appropriate use criteria for revascularization [11]. We strongly encourage rigorous application of these guidelines in the selection of patients for CTO-PCI, even though there is a paradoxical downgrading in the appropriateness of CTO-PCI as compared with non-CTO-PCI [12].
Table 1. Summary of chronic total occlusion-percutaneous coronary intervention trials.

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Patients (n)</th>
<th>Follow-up (years)</th>
<th>Stents used</th>
<th>Survival rates (%), success vs failure (p-value)</th>
<th>Long-term mortality, OR (95% CI)</th>
<th>MACE free, OR (95% CI)</th>
<th>Angina free, OR (95% CI)</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drozd et al. (1996–2003)</td>
<td>498</td>
<td>3</td>
<td>PTCA (NA), BMS (NA)</td>
<td>97.5 vs 97.3 (p = NS)</td>
<td>0.74 (0.23–22.37)</td>
<td>0.84 (0.54–51.31)</td>
<td>0.665 (0.446–440.991)</td>
<td>[29]</td>
</tr>
<tr>
<td>Chen et al. (2004–2005)</td>
<td>152</td>
<td>3</td>
<td>DES (100%)</td>
<td>98.5 vs 85.0 (p = 0.010)</td>
<td>0.087 (0.014–010.56)</td>
<td></td>
<td></td>
<td>[30]</td>
</tr>
<tr>
<td>Arslan et al. (1999–2003)</td>
<td>262</td>
<td>2.8</td>
<td>DES (92%)</td>
<td>85.5 vs 72.2 (p = 0.013)</td>
<td>0.409 (0.218–210.766)</td>
<td></td>
<td></td>
<td>[31]</td>
</tr>
<tr>
<td>Suero et al. (1980–1999)</td>
<td>2005</td>
<td>10</td>
<td>PTCA (93%), BMS (7%)</td>
<td>73.5 vs 65.0 (p = 0.001)</td>
<td>0.67 (0.54–50.83)</td>
<td></td>
<td></td>
<td>[32]</td>
</tr>
<tr>
<td>Olivari et al. (1999–2000)</td>
<td>369</td>
<td>1</td>
<td>BMS (90%)</td>
<td>99.7 vs 96.4 (p = 0.04)</td>
<td>0.19 (0.03–01.14)</td>
<td>0.41 (0.22–00.76)</td>
<td>0.382 (0.189–180.772)</td>
<td>[33]</td>
</tr>
<tr>
<td>Hoye et al. (1992–2002)</td>
<td>871</td>
<td>5</td>
<td>BMS (81%), PTCA (19%)</td>
<td>93.5 vs 88.0 (p = 0.02)</td>
<td>0.52 (0.32–30.84)</td>
<td>0.41 (0.31–30.54)</td>
<td></td>
<td>[34]</td>
</tr>
<tr>
<td>Aziz et al. (2000–2004)</td>
<td>543</td>
<td>2</td>
<td>BMS (81%), DES (17%)</td>
<td>98.0 vs 94.2 (p = 0.05)</td>
<td>0.31 (0.13–10.76)</td>
<td></td>
<td></td>
<td>[35]</td>
</tr>
<tr>
<td>Prasad et al. (1979–2005)</td>
<td>1262</td>
<td>10</td>
<td>DES (29%), BMS (NR)</td>
<td>72 vs 77 (p = 0.03)</td>
<td>0.82 (0.62–61.08)</td>
<td></td>
<td></td>
<td>[36]</td>
</tr>
<tr>
<td>Labriolle et al. (2003–2005)</td>
<td>172</td>
<td>2</td>
<td>BMS (10%), DES (84%)</td>
<td>95.1 vs 94.7 (p = 0.28)</td>
<td>1.25 (0.25–26.27)</td>
<td>6.36 (1.45–27.87)</td>
<td></td>
<td>[37]</td>
</tr>
<tr>
<td>Valenti et al. (2003–2006)</td>
<td>486</td>
<td>4</td>
<td>DES (100%)</td>
<td>91.6 vs 87.4 (p = 0.03)</td>
<td>0.38 (0.19–10.77)</td>
<td>0.95 (0.59–51.54)</td>
<td></td>
<td>[38]</td>
</tr>
<tr>
<td>Lee et al. (2003–2006)</td>
<td>333</td>
<td>3</td>
<td>DES (100%)</td>
<td>96.7 vs 94.7 (p = 0.28)</td>
<td>0.171 (0.074–70.395)</td>
<td></td>
<td></td>
<td>[39]</td>
</tr>
<tr>
<td>Mehran et al. (1998–2007)</td>
<td>1791</td>
<td>5</td>
<td>BMS (34%), DES (66%)</td>
<td>97.0 vs 94.2 (p &lt; 0.01)</td>
<td>0.63 (0.40–41.0)</td>
<td></td>
<td></td>
<td>[40]</td>
</tr>
<tr>
<td>Jones et al. (2003–2010)</td>
<td>836</td>
<td>5</td>
<td>DES (76%)</td>
<td>95.5 vs 82.8 (NR)</td>
<td>0.28 (0.15–10.52)</td>
<td>HR</td>
<td></td>
<td>[41]</td>
</tr>
<tr>
<td>Noguchi et al. (1986–1996)</td>
<td>226</td>
<td>4.3</td>
<td>PTCA (100%)</td>
<td>95.0 vs 84.0 (p &lt; 0.05)</td>
<td>0.28 (0.11–10.72)</td>
<td>1.00 (0.58–51.72)</td>
<td></td>
<td>[42]</td>
</tr>
<tr>
<td>Angioi et al. (1995)</td>
<td>201</td>
<td>6</td>
<td>PTCA (100%)</td>
<td>97 vs 92 (p &lt; 0.05)</td>
<td>0.37 (0.10–11.40)</td>
<td>1.2 (0.69–62.11)</td>
<td>0.337 (0.185–180.613)</td>
<td>[43]</td>
</tr>
<tr>
<td>Finci et al. (1986–1988)</td>
<td>200</td>
<td>2</td>
<td>PTCA (100%)</td>
<td>95.0 vs 97.0 (p = NS)</td>
<td>1.70 (0.40–47.32)</td>
<td>0.71 (0.40–41.26)</td>
<td>0.265 (0.146–140.482)</td>
<td>[44]</td>
</tr>
<tr>
<td>Warren et al. (1986–1988)</td>
<td>44</td>
<td>2.6</td>
<td>PTCA (100%)</td>
<td>NA</td>
<td>NA</td>
<td>0.20 (0.286–283.373)</td>
<td></td>
<td>[45]</td>
</tr>
<tr>
<td>Sathe et al. (1984–1992)</td>
<td>136</td>
<td>2.8</td>
<td>PTCA (100%)</td>
<td>98.0 vs 94.0 (p &gt; 0.1)</td>
<td>0.40 (0.09–1.73)</td>
<td>RR</td>
<td>1.26 (0.85–81.87)</td>
<td>35 vs 56%, p &lt; 0.003</td>
</tr>
<tr>
<td>Ivanhoe et al. (1980–1988)</td>
<td>480</td>
<td>4</td>
<td>PTCA (100%)</td>
<td>99.0 vs 96.0 (p = 0.006)</td>
<td>0.21 (0.05–0.83)</td>
<td>0.722 (0.04–0.95)</td>
<td></td>
<td>[47]</td>
</tr>
<tr>
<td>Niccoli et al. (2005–2009)</td>
<td>317</td>
<td>3</td>
<td>DES (100%)</td>
<td>97.0 vs 92.0 (p = 0.11)</td>
<td>1.3 (0.6–2.3) HR for single CTO only</td>
<td>1.2 (0.5–2.2) HR SV</td>
<td></td>
<td>[48]</td>
</tr>
</tbody>
</table>

†Patients with successful CTO-PCI in these studies were free from coronary artery bypass grafting compared with unsuccessful CTO-PCI. BMS: Bare metal stent; CTO: Chronic total occlusion; DES: Drug-eluting stent; HR: Hazard ratio; MACE: Major adverse cardiac events; NA: Not available; OR: Odds ratio; PCI: Percutaneous coronary intervention; PTCA: Percutaneous transluminal coronary angioplasty; RR: Risk ratio.
**Economic disincentives**

There are several economic barriers to performing and referring patients for CTO-PCI. There is only one study that attempted to determine the cost-effectiveness of CTO-PCI from a societal perspective. Many institutions are concerned with the increased supply costs relative to non-CTO-PCI, lost productivity due to prolonged procedures and the potential for lost coronary artery bypass graft volume. Some operators worry about the potential loss of patients or professional reputation after referring patients to a CTO-PCI center.

An estimated 600,000 to 1.8 million Americans suffer from refractory angina [11] at an estimated lifetime expense of US$1 million each. Upwards of 70% of these patients are deemed non-revascularizable due to a CTO. Chronic angina is commonly experienced by patients with CTOs [9,13,14] and successful CTO-PCI is associated with improvements in angina status and quality of life (Table 1). These treatment costs of patients suffering from chronic stable angina exceeds that of other conditions such as non-cancer pain [15]. In a comparative cost-effective analysis using a Markov model the cost of CTO-PCI was higher as compared with optimal medical therapy (OMT). However, CTO-PCI was associated with much greater quality-adjusted life-years (2.38 vs 1.99), yielding a better cost-effectiveness ratio [16]. Again, the case of Mr J highlights the added costs to society of undertreated CTOs, where repeated hospital admissions, imaging and catheter studies were performed before his problem was ultimately successfully addressed.

Institutional concern over higher supply costs is warranted. The tool kit required to implement a CTO program costs approximately US$70,000. Added to that is the expense of higher stent use per case (typically 2.4 stents per case compared with 1.7 per case in non-CTO-PCI) [4]. Given the parsimonious increase in reimbursement for complex PCI compared with non-CTO (i.e., routine) PCI in the USA, hospitals are right to question the fairness of the current reimbursement system in the USA. Outside the USA similar restrictions on procedural reimbursements exist that effectively preclude the use of newer, more expensive technologies. Clearly better data on the cost and cost-effectiveness of CTO as compared with medical therapy is needed so that a complete understanding of the value of CTO-PCI can be obtained. It may be penny-wise and pound-foolish to continue in the current state of CTO-PCI denial for patients suffering with refractory angina, from a payor perspective.

From a hospital perspective, Karmpaliotis and colleagues determined that the contribution margin of CTO-PCI was only US$400 less for CTO than non-CTO-PCI [17]. This obviously requires careful management of payor mix and could be drastically impacted by healthcare reimbursement changes (e.g., the two midnight rule by Medicare) or price gouging by CTO device vendors. Nevertheless, we as practitioners and

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Patients (n)</th>
<th>Follow-up (years)</th>
<th>Stents used</th>
<th>Survival rates (%), success vs failure (p-value)</th>
<th>Long-term mortality, OR (95% CI)</th>
<th>MACE free, OR (95% CI)</th>
<th>Angina free, OR (95% CI)</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi et al.†</td>
<td>1332</td>
<td>10</td>
<td>BMS (NA), DES (NA)</td>
<td>77.6 vs 66.2 (p &lt; 0.05)</td>
<td>87.6 vs 65.8%, p &lt; 0.01</td>
<td>[49]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yang et al.</td>
<td>136</td>
<td>2</td>
<td>DES (100%)</td>
<td>92.0 vs 79.6 (p = 0.036)</td>
<td>0.145 (0.047–40.446)</td>
<td>0.430 (0.220–220.838)</td>
<td>[50]</td>
<td></td>
</tr>
<tr>
<td>Borgia et al</td>
<td>302</td>
<td>4</td>
<td>DES (100%)</td>
<td>97 vs 90.4 (p = 0.03)</td>
<td>0.58 (0.28–21.22)</td>
<td>0.34 (0.23–20.52) RR</td>
<td>81.6 vs 55.0%, p &lt; 0.001</td>
<td>[51]</td>
</tr>
<tr>
<td>Jolicouer et al</td>
<td>346</td>
<td>5.6</td>
<td>BMS (49%), DES (51%)</td>
<td>87 vs 79.9 (p = 0.16)</td>
<td>0.614 (0.194–191.943)</td>
<td>[52]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joyal et al.</td>
<td>7288</td>
<td>6 (weighted)</td>
<td>NA</td>
<td>85.7 vs 82.5 (p = 0.07)</td>
<td>0.56 (0.43–40.72)</td>
<td>0.81 (0.55–51.21)</td>
<td>0.45 (0.30–30.67)</td>
<td>[53]</td>
</tr>
<tr>
<td>Pancholy et al</td>
<td>12,970</td>
<td>3.7 (weighted)</td>
<td>NA</td>
<td>0.54 (0.45–40.65)</td>
<td>0.70 (0.59–50.83)</td>
<td>NR</td>
<td>[55]</td>
<td></td>
</tr>
</tbody>
</table>

†Patients with successful CTO-PCI in these studies were free from coronary artery bypass grafting compared with unsuccessful CTO-PCI.

BMS: Bare metal stent; CTO: Chronic total occlusion; DES: Drug-eluting stent; HR: Hazard ratio; MACE: Major adverse cardiac events; NA: Not available; OR: Odds ratio; PCI: Percutaneous coronary intervention; PTCA: Percutaneous transluminal coronary angioplasty; RR: Risk ratio.
patient advocates must in every case do what is best for
patients and continue to argue for better reimbursement
for these procedures to the extent that the data supports
them, and work with vendors to negotiate fair prices for
CTO specialized equipment. A more detailed cost anal-
ysis of CTO-PCI is underway in the US multi-center
OPEN-CTO study.

Lost cath lab and operator productivity due to pro-
longed procedures is being addressed by improved pro-
cedural efficiency as has been demonstrated using the
hybrid approach to CTO-PCI [18], which is discussed
below. This issue is less acute recently as interventional
volumes have declined [19] and hospitals interested in
filling this time look toward new business opportunities
so that their fixed costs are not wasted.

Lost CABG volume is not a necessary effect of initiat-
ing a CTO-PCI program. CABG remains an attractive
alternative to PCI for patients with intermediate and
high disease burden [20]. Additionally, once recognized
for expertise in the management of complex coronary
artery disease, CTO centers often experience an increase
in bypass surgery volume.

Operators committed to the right therapy for the
right patient every time should also consider that bypass
surgery for CTOs may not always be the best solution
for the patient. Durability of a saphenous vein graft to
an RCA or LCX CTO is limited. One report suggested
1-year patency rates as low as 23% [21]. Finally, many
patients with CTO have already undergone CABG.
Repeat coronary artery bypass graft surgery for an
isolated RCA or LCX saphenous vein graft is not war-
ranted when native vessel CTO-PCI is an option. In the
US 30% of CTO-PCIs are performed on patients with
prior CABG [22].

The loss of a patient to a referral center remains a
prevalent fear that limits any center of excellence model
in the delivery of cardiovascular care. However, in the
age of informed medical consumerism and direct-to-
consumer marketing, many CTO centers will seek
to inform the public of the PCI option for CTOs. As
patients begin to understand that they are not receiving
the same information from their doctors, the negative
impact on a medical practice could be just as significant.

Lack of physician training & technical
expertise
Advancements in guidewire technology, refinements
in support and balloon catheters, novel re-entry
deVICES and the retrograde technique have all contrib-
uted to higher procedural success, adequate safety and
improved procedural efficiency [23]. The complex
technical decision-making of CTO-PCI has been simplified
by the development and implementation of the hybrid
approach [24,25]. This approach is teachable and has now
been adopted at over 100 centers in the USA and abroad.
While not every interventionalist can or should become
a CTO operator, enough will adopt this approach so
that every patient will soon have access to a CTO-PCI
operator. Operators and institutions interested in devel-
oping a CTO-PCI program now have at their disposal a

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Patients (n)</th>
<th>Follow-up</th>
<th>LVEF method</th>
<th>LVEF improvement</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dzavik et al., TOSCA (2001)</td>
<td>244</td>
<td>6 months</td>
<td>Ventriculography</td>
<td>59.4 + 11% to 61.0 + 11%; p = 0.03</td>
<td>[56]</td>
</tr>
<tr>
<td>Chung et al. (2003)</td>
<td>130</td>
<td>6 months</td>
<td>Ventriculography</td>
<td>53.2 + 16.32 to 57.3 + 20.1; p = 0.001</td>
<td>[57]</td>
</tr>
<tr>
<td>Kirschbaum et al. (2008)</td>
<td>21</td>
<td>3 years</td>
<td>C-MRI</td>
<td>60 + 9% to 63 + 11%; p = 0.11</td>
<td>[58]</td>
</tr>
<tr>
<td>Baks et al. (2006)</td>
<td>27</td>
<td>5 months</td>
<td>C-MRI</td>
<td>61 ± 9% to 62 ± 11%; p = 0.54</td>
<td>[59]</td>
</tr>
<tr>
<td>Erdogan et al. (2012)</td>
<td>129</td>
<td>1 month</td>
<td>RT3DE</td>
<td>56.3 + 9.8 to 58.3 + 10.2%; p &lt; 0.001</td>
<td>[60]</td>
</tr>
<tr>
<td>Roifman et al. (2013)</td>
<td>30</td>
<td>Post-procedure</td>
<td>C-MRI</td>
<td>50 ± 13% to 54 ± 11%; p &lt; 0.01</td>
<td>[61]</td>
</tr>
<tr>
<td>Yue et al. (2012)</td>
<td>32</td>
<td>6 weeks</td>
<td>RT3DE</td>
<td>59.9 ± 7.2 to 67.5 ± 8.7%; p &lt; 0.05 (no previous MI)</td>
<td>[62]</td>
</tr>
<tr>
<td>Fettser et al. (2011)</td>
<td>154</td>
<td>6 months</td>
<td>2D Echo</td>
<td>50.4 + 10.7 to 56.1 + 11.3%; p &lt; 0.0001</td>
<td>[63]</td>
</tr>
<tr>
<td>Ermis et al. (2005)</td>
<td>35</td>
<td>Varied</td>
<td>2D Echo</td>
<td>51 ± 7% to 58 ± 6%; p &lt; 0.001</td>
<td>[64]</td>
</tr>
</tbody>
</table>

LVEF: Left ventricular ejection fraction.
wealth of resources to help them in this effort. National and international meetings committed to teaching CTO-PCI techniques, web-based training modules such as www.CTOfundamentals.org, and systematic industry-sponsored proctoring are readily available.

**Conclusion**
The case of Mr J highlights many of the challenges in delivering appropriate percutaneous coronary interventional services to patients with complex coronary artery disease. Patients with CTOs are routinely given excuses by their physicians for not considering PCI. Many patients who are excellent candidates for PCI are offered medical therapy or bypass surgery instead. While a better understanding of the benefits of CTO-PCI might help, the ultimate solution lies in teaching interventional cardiologists about the solutions to the barriers to CTO-PCI. The hybrid approach is designed to address most of these concerns. With the hybrid approach success rates over 90% [26], major cardiac adverse events (MACE) less than 4% [27] and highly efficient procedures (80% can be completed in less than 90 min) [28] can be achieved by enough operators to meet the goal of providing access to PCI for every appropriately selected patient with a CTO.

**Future perspective**
The field of CTO-PCI has evolved. With the development of new techniques and implementation of the Hybrid Approach success rates of 90% with low complication rates and lower procedure times are possible. Barriers to CTO-PCI adoption still exist in the minds of many operators and institutions. The Hybrid Approach [24,25] is teachable and has now been adopted at over 100 centers in the USA and abroad. While not every interventionalist can or should become a CTO operator, enough will adopt this approach so that every patient will soon have access to a CTO-PCI when it is appropriate. Operators and Institutions interested in developing a CTO-PCI program now have at their disposal a wealth of resources to help them in this effort. National and international meetings committed to teaching CTO-PCI techniques, web based training modules such as www.CTOfundamentals.org, and systematic industry-sponsored proctoring are readily available. To further inform physicians and patients in this decision trials designed to better define the benefits, appropriateness and cost of CTO-PCI such as the OPEN CTO (www.clinicaltrials.gov) are underway.

**Financial & competing interests disclosure**
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

---

**Executive summary**

- A case example of inappropriately deferred percutaneous coronary intervention (PCI) is presented to highlight the problem of underutilization of PCI for chronic total occlusion (CTO).
- The evidence suggesting that CTOs are being treated or not treated based on physician preference and institutional biases, not patient needs, is reviewed.
- The reasons for not treating appropriate patients with PCI are discussed along with the evidence refuting these excuses.
- Solutions to these barriers to CTO-PCI adoption are described.

---

**References**
Papers of special note have been highlighted as:

Clinical characteristics associated with higher mortality in non-revascularized CTO.

Cost-effectiveness of CTO-PCI.

How the use of the hybrid algorithm improves CTO-PCI success in the real world.

The use of the hybrid algorithm in CTO-PCI.

Chronic total occlusion angioplasty: no more excuses


How the use of the hybrid algorithm improves CTO-PCI success in the real world.


Illustrates the incidence of failure or non-arterial coronary artery bypass grafts.


Whitlow PL, Burke MN, Lombardi WL et al. Use of a novel crossing and re-entry system in coronary chronic total occlusions that have failed standard crossing techniques: results of the FAST-CTOs (Facilitated Antegrade Steering Technique in Chronic Total Occlusions) trial. JACC Cardiovasc. Interv. 5(4), 393–401 (2012).


The use of the hybrid algorithm in CTO-PCI.


Perspective  Sapontis & Grantham


Chronic total occlusion angioplasty: no more excuses  

**Perspective**

- Up-to-date meta-analysis on survival of successful CTO-PCI versus failed CTO-PCI.


